- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01471223
Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study (CTS)
18. september 2017 opdateret af: Bristol-Myers Squibb
Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study (CTS)
The purpose of the study is to estimate the incidence rates of Post-transplant Lymphoproliferative Disorder (PTLD), malignancy and hospitalized infections in adult kidney-only transplant recipients treated with Belatacept, and compared the incidences to the incidences in those treated with Calcineurin inhibitor (CNI) based regimens at the time of transplantation.
Studieoversigt
Status
Afsluttet
Betingelser
Detaljeret beskrivelse
Time Perspective: Prospective design, Retrospective data collection and analysis
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
89
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Patients undergoing 1st kidney only transplantation, whose transplant centers participate in CTS and who are treated with Belatacept or a CNI based regimen at the time of transplantation
Beskrivelse
Inclusion Criteria:
- 1st kidney only transplant during study, at one of the transplant centers participating in CTS, received Belatacept or a CNI at the time of transplantation
Exclusion Criteria:
- Patients with a history of malignancy
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
---|
Patients receiving Belatacept in CTS
Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving Belatacept at the time of transplantation
|
Patients receiving CNI in CTS
Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving CNI at the time of transplantation
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Incidences of Post-transplant Lymphoproliferative Disorder (PTLD)
Tidsramme: 5 years post transplantation
|
5 years post transplantation
|
Incidences of hospitalized infections
Tidsramme: 2 years post transplantation
|
2 years post transplantation
|
Incidences of malignancy
Tidsramme: 5 years post transplantation
|
5 years post transplantation
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Incidence rates of PTLD in adult subgroups of Belatacept- vs. CNI-treated, kidney-only transplant recipients defined by donor-recipient Epstein Barr virus (EBV) serostatus and by age groups
Tidsramme: Every 6 months and 12 months
|
Every 6 months and 12 months
|
|
Location, mortality, and tumor type of all PTLD cases in adult kidney-only transplant recipients treated with Belatacept vs. CNI-based regimens at the time of transplantation and in subgroups of these transplant recipients
Tidsramme: Every 6 months and 12 months
|
Subgroups of the transplant recipients defined by donor-recipient EBV serostatus at the time of transplantation
|
Every 6 months and 12 months
|
Cumulative incidence of hospitalized infections in adult kidney-only transplant recipients treated with Belatacept vs. CNI-based regimens at the time of transplantation
Tidsramme: Every 6 months and 12 months
|
Hospitalized infections for the following infection groups:
|
Every 6 months and 12 months
|
Incidence rates of graft rejection in adult kidney-only transplant recipients treated with Belatacept vs. CNI-based regimens at the time of transplantation
Tidsramme: Every 6 months and 12 months
|
Every 6 months and 12 months
|
|
Incidence rates of graft failure in adult kidney-only transplant recipients treated with Belatacept vs. CNI-based regimens at the time of transplantation
Tidsramme: Every 6 months and 12 months
|
Every 6 months and 12 months
|
|
Mortality rate of composite bacterial, fungal, viral, tuberculosis, herpes, and CMV infections
Tidsramme: 2 years post transplantation
|
2 years post transplantation
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
31. marts 2012
Primær færdiggørelse (Faktiske)
8. august 2017
Studieafslutning (Faktiske)
8. august 2017
Datoer for studieregistrering
Først indsendt
10. november 2011
Først indsendt, der opfyldte QC-kriterier
14. november 2011
Først opslået (Skøn)
15. november 2011
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
19. september 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
18. september 2017
Sidst verificeret
1. september 2017
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- IM103-089
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Nyretransplantation
-
Hopital FochRekrutteringForældrestatus | Transplantation af lunge | Transplantation af nyreFrankrig
-
Assistance Publique - Hôpitaux de ParisRekrutteringTransplantation | Haplo-identisk transplantationFrankrig
-
Icahn School of Medicine at Mount SinaiThe Hospital for Sick Children; Baylor College of Medicine; Children's Hospital... og andre samarbejdspartnereAktiv, ikke rekrutterendeTransplantationForenede Stater, Canada
-
CareDxAfsluttetTransplantationForenede Stater
-
University of California, San FranciscoBristol-Myers SquibbTrukket tilbageTransplantation
-
Southern Medical University, ChinaThird Affiliated Hospital, Sun Yat-Sen University; 181 Central Hospital...Afsluttet
-
Astellas Pharma IncAfsluttetTransplantationFrankrig, Italien, Polen, Tyskland, Spanien, Belgien, Schweiz, Finland, Tjekkiet, Ungarn, Østrig, Danmark, Sverige
-
Astellas Pharma IncAfsluttetTransplantationFrankrig, Spanien, Tyskland, Det Forenede Kongerige, Irland, Polen
-
University Health Network, TorontoThe Physicians' Services Incorporated FoundationAfsluttet